HeartBeam (NASDAQ: BEAT) has announced a strategic reorganization aimed at accelerating execution, expanding global market reach, and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. The company said the new structure is designed to streamline decision-making, improve accountability, and reduce costs. Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams, while former CEO Robert Eno transitions into a consulting role.
The reorganization centers on leveraging HeartBeam's patented 3D ECG platform across multiple healthcare channels, including partnerships with governments, health systems, ECG manufacturers, and wearable device companies. The company is building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment, and is advancing development beyond arrhythmia toward heart attack detection.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.
The company's strategy includes expanding partnerships to accelerate adoption of its technology. For more details on the reorganization, the full press release is available at https://ibn.fm/CTxXi. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the company's SEC filings. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
